Tamas Habon

Prof. Tamas Habon

University of Pecs, Medical School, 1st Dept. Med, Div. Cardiology
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RGRoland Gal
Roland Gal
LDLaszlo Deres
Laszlo Deres
KTKalman Toth
Kalman Toth
RHRobert Halmosi
Robert Halmosi
THTamas Habon
Tamas Habon
Cardiovascular diseases are the leading causes of death worldwide. The cardioprotective effects of natural polyphenols such as resveratrol (3,5,4-trihydroxystilbene) have been extensively investigated throughout recent decades. Many studies of RES have focused on its favorable effects on pathological conditions related to cardiovascular diseases and their risk factors. The aim of this review was to summarize the wide beneficial effects of resveratrol on the cardiovascular system, including signal transduction pathways of cell longevity, energy metabolism of cardiomyocytes or cardiac remodeling, and its anti-inflammatory and antioxidant properties. In addition, this paper discusses the significant preclinical and human clinical trials of recent years with resveratrol on cardiovascular system. Finally, we present a short overview of antiviral and anti-inflammatory properties and possible future perspectives on RES against COVID-19 in cardiovascular diseases.

1 February 1999 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
ESEszter Szabados
Eszter Szabados
GFGaborM Fischer
GaborM Fischer
KTKalman Toth
Kalman Toth
BCBela Csete
Bela Csete
BNBalazs Nemeti
Balazs Nemeti
BSBalazs Sumegi
Balazs Sumegi

20 September 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LKLóránd Kiss
Lóránd Kiss
GFGabriella Fűr
Gabriella Fűr
PMPéter Mátrai
Péter Mátrai
PHPéter Hegyi
Péter Hegyi
EIEmese Ivány
Emese Ivány
Zoltán RakonczayZoltán Rakonczay
Zoltán Rakonczay
Elevated serum triglyceride concentration (seTG, >1.7 mM or >150 mg/dL) or in other words hypertriglyceridemia (HTG) is common in the populations of developed countries. This condition is accompanied by an increased risk for various diseases, such as acute pancreatitis (AP). It has been proposed that HTG could also worsen the course of AP. Therefore, in this meta-analysis, we aimed to compare the effects of various seTGs on the severity, mortality, local and systemic complications of AP, and on intensive care unit admission. 16 eligible studies, including 11,965 patients were retrieved from PubMed and Embase. The results showed that HTG significantly elevated the odds ratio (OR = 1.72) for severe AP when compared to patients with normal seTG (5.6 mM or >11.3 mM versus <5.6 mM or <11.3 mM, respectively. We conclude that the presence of HTG worsens the course and outcome of AP, but we found no significant difference in AP severity based on the extent of HTG.

1 January 2002 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
BHBeata Horvath
Beata Horvath
ZMZsolt Marton
Zsolt Marton
RHRobert Halmosi
Robert Halmosi
TATamas Alexy
Tamas Alexy
LSLaszlo Szapary
Laszlo Szapary
KTKalman Toth
Kalman Toth
Oxygen-free radicals play an important role in several physiologic and pathophysiologic processes. In pathologic circumstances, they can modify and damage biologic systems. Because oxygen-free radicals are involved in a wide range of diseases (cerebrovascular, cardiovascular, etc.), scavenging these radicals should be considered as an important therapeutic approach. In our in vitro study, we investigated the antioxidant capacity of three drugs: pentoxiphylline (Sigma Aldrich, St. Louis, MO, USA) piracetam (Sigma Aldrich), and vinpocetine (Richter Gedeon RT, Budapest, Hungary). Phenazine methosulphate was applied to generate free radicals, increasing red blood cell rigidity. Filtration technique and potassium leaking were used to detect the cellular damage and the scavenging effect of the examined drugs. According to our results, at human therapeutic serum concentration, only vinpocetine (Richter Gedeon RT) had significant (p < 0.01) scavenging activity with a protective effect that increased further at higher concentrations. Pentoxiphylline (Sigma Aldrich) and piracetam (Sigma Aldrich) did not have significant antioxidant capacity at therapeutic concentrations, but increasing their concentrations (pentoxiphylline at 100-times, and piracetam at 10-times higher concentrations) led to a significant (p < 0.01) scavenger effect. Our findings suggest that this pronounced antioxidant effect of vinpocetine and even the milder scavenging capacity of pentoxiphylline and piracetam may be of value in the treatment of patients with cerebrovascular disorders, but merits further investigations.

25 June 2018 in Helicobacter
Verified
Journal Article
Open access
PDF file
BEBalint Eross
Balint Eross
NFNelli Farkas
Nelli Farkas
Aron VinczeAron Vincze
Aron Vincze
BTBenedek Tinusz
Benedek Tinusz
LSLászló Szapáry
László Szapáry
PHPéter Hegyi
Péter Hegyi
Introduction: The prevalence of Helicobacter pylori infection (HPI) has been decreasing in developed countries, with an increasing prevalence of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) at the same time. The aim of our meta‐analysis was to quantify the risk of BE in the context of HPI.Methods: A systematic search was conducted in 3 databases for studies on BE with data on prevalence of HPI from inception until December 2016. Odds ratios for BE in HPI were calculated by the random effects model with subgroup analyses for geographical location, presence of dysplasia in BE, and length of the BE segment.Results: Seventy‐two studies were included in the meta‐analysis, including 84 717 BE cases and 390 749 controls. The overall analysis showed that HPI reduces the risk of BE; OR = 0.68 (95% CI: 0.58‐0.79, P < .001). Subgroup analyses revealed risk reduction in Asia OR = 0.53 (95% CI: 0.33‐0.84, P = .007), Australia OR = 0.56 (95% CI: 0.39‐0.80, P = .002), Europe OR = 0.77 (95% CI: 0.60‐0.98, P = .035), and North‐America OR = 0.59 (95% CI: 0.47‐0.74, P < .001). The risk was significantly reduced for dysplastic BE, OR = 0.37 (95% CI: 0.26‐0.51, P < .001) for non‐dysplastic BE, OR = 0.51 (95% CI: 0.35‐0.75, P = .001), and for long segment BE, OR = 0.25 (95% CI: 0.11‐0.59, P = .001) in case of HPI.Conclusions: This extensive meta‐analysis provides additional evidence that HPI is associated with reduced risk of BE. Subgroup analyses confirmed that this risk reduction is independent of geographical location. HPI is associated with significantly lower risk of dysplastic, non‐dysplastic, and long segment BE.

1 October 2018 in Pancreas
Verified
Journal Article
Open access
ICIrina Mihaela Cazacu
Irina Mihaela Cazacu
NFNelli Farkas
Nelli Farkas
Andras GaramiAndras Garami
Andras Garami
MBMárta Balaskó
Márta Balaskó
BMBernadett Mosdósi
Bernadett Mosdósi
Peter HegyiPeter Hegyi
Peter Hegyi
Objective: The aim of this study was to evaluate the connection between pancreatic cancer (PC) and genetic variants associated with chronic pancreatitis via systematic review and meta-analysis.Methods: The data search was performed in 3 major databases (PubMed, Embase, and Cochrane Library). The selected studies have looked into the presence of the pancreatitis-associated genes in patients with PC and in control subjects, the outcome being the frequency of the mutations in the 2 groups. For the binary outcomes, pooled odds ratio (OR) and 95% confidence interval (CI) were calculated.Results: Ten articles proved to be eligible for the qualitative synthesis, and 8 articles were suitable for statistical analysis. Six case-control studies, comprising 929 PC cases and 1890 control subjects for serine protease inhibitor Kazal type 1 (SPINK1) mutations, and 5 case-control studies, comprising 1674 PC cases and 19,036 control subjects forCFTRmutations, were enrolled in our analysis.SPINK1mutations showed no association with PC (OR, 1.52; 95% CI, 0.67–3.45;P= 0.315), whereas mutations inCFTRmodestly increased the risk of PC (OR, 1.41; 95% CI, 1.07–1.84;P= 0.013).Conclusion: Our meta-analysis showed that mutations inCFTRmodestly increase the risk of PC, whereas no association was found betweenSPINK1and PC.